Sangamo Therapeutics (NASDAQ:SGMO) Receives Equal Weight Rating from Barclays

Barclays reissued their equal weight rating on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a research report released on Friday morning, MarketBeat reports. The firm currently has a $1.00 target price on the biopharmaceutical company’s stock, down from their previous target price of $5.00.

A number of other equities research analysts have also recently issued reports on SGMO. Wall Street Zen upgraded Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of Sangamo Therapeutics in a research note on Wednesday, October 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Sangamo Therapeutics in a research report on Thursday, September 4th. Three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $3.83.

Sangamo Therapeutics Stock Performance

Shares of Sangamo Therapeutics stock traded up $0.01 on Friday, hitting $0.47. The company had a trading volume of 6,046,373 shares, compared to its average volume of 5,817,381. The stock has a 50 day moving average of $0.60 and a 200-day moving average of $0.57. Sangamo Therapeutics has a 1 year low of $0.41 and a 1 year high of $3.18. The stock has a market capitalization of $142.35 million, a price-to-earnings ratio of -1.63 and a beta of 1.25.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.08). The firm had revenue of $0.58 million during the quarter, compared to the consensus estimate of $34.40 million. Sangamo Therapeutics had a negative return on equity of 293.05% and a negative net margin of 77.48%. Equities analysts anticipate that Sangamo Therapeutics will post -0.46 earnings per share for the current year.

Institutional Trading of Sangamo Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in Sangamo Therapeutics by 23.9% in the 3rd quarter. Vanguard Group Inc. now owns 11,615,150 shares of the biopharmaceutical company’s stock worth $7,817,000 after purchasing an additional 2,240,422 shares in the last quarter. Wasatch Advisors LP grew its stake in shares of Sangamo Therapeutics by 17.7% during the 2nd quarter. Wasatch Advisors LP now owns 8,084,419 shares of the biopharmaceutical company’s stock valued at $4,376,000 after purchasing an additional 1,215,653 shares during the period. GSA Capital Partners LLP grew its position in Sangamo Therapeutics by 63.1% during the third quarter. GSA Capital Partners LLP now owns 3,662,478 shares of the biopharmaceutical company’s stock valued at $2,466,000 after buying an additional 1,417,029 shares during the period. Geode Capital Management LLC increased its stake in shares of Sangamo Therapeutics by 2.1% in the 2nd quarter. Geode Capital Management LLC now owns 2,332,279 shares of the biopharmaceutical company’s stock worth $1,263,000 after purchasing an additional 48,829 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. increased its position in Sangamo Therapeutics by 74.8% in the first quarter. Jacobs Levy Equity Management Inc. now owns 1,297,785 shares of the biopharmaceutical company’s stock worth $851,000 after buying an additional 555,323 shares in the last quarter. 56.92% of the stock is owned by institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.